These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

158 related articles for article (PubMed ID: 434676)

  • 1. Prolonged disease-free survival in Hodgkin's disease with MOPP reinduction after first relapse.
    Fisher RI; DeVita VT; Hubbard SP; Simon R; Young RC
    Ann Intern Med; 1979 May; 90(5):761-3. PubMed ID: 434676
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Long-term follow-up with ABDIC salvage chemotherapy of MOPP-resistant Hodgkin's disease.
    Tannir N; Hagemeister F; Velasquez W; Cabanillas F
    J Clin Oncol; 1983 Jul; 1(7):432-9. PubMed ID: 6199478
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Salvage chemotherapy with ABVD in MOPP-resistant Hodgkin's disease.
    Santoro A; Bonfante V; Bonadonna G
    Ann Intern Med; 1982 Feb; 96(2):139-43. PubMed ID: 6174060
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Randomized study for the treatment of adult advanced Hodgkin's disease: mechlorethamine, vincristine, procarbazine, and prednisone (MOPP) versus lomustine, vinblastine, and prednisone.
    Liebman HA; Hum GJ; Sheehan WW; Ryden VM; Bateman JR
    Cancer Treat Rep; 1983 May; 67(5):413-9. PubMed ID: 6342771
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Treatment of advanced-stage massive mediastinal Hodgkin's disease: the case for combined modality treatment.
    Longo DL; Russo A; Duffey PL; Hubbard SM; Glatstein E; Hill JB; Jaffe ES; Young RC; DeVita VT
    J Clin Oncol; 1991 Feb; 9(2):227-35. PubMed ID: 1988570
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Alternating drug combinations in the treatment of advanced Hodgkin's disease.
    Santoro A; Bonadonna G; Bonfante V; Valagussa P
    N Engl J Med; 1982 Apr; 306(13):770-5. PubMed ID: 6174865
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Outcome of patients with Hodgkin's disease failing after primary MOPP-ABVD.
    Bonfante V; Santoro A; Viviani S; Devizzi L; Balzarotti M; Soncini F; Zanini M; Valagussa P; Bonadonna G
    J Clin Oncol; 1997 Feb; 15(2):528-34. PubMed ID: 9053474
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A comparison of nitrogen mustard, vincristine, procarbazine, and prednisone (MOPP) vs. nitrogen mustard in advanced Hodgkin's disease.
    Huguley CM; Durant JR; Moores RR; Chan YK; Dorfman RF; Johnson L
    Cancer; 1975 Oct; 36(4):1227-40. PubMed ID: 1175125
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cyclic delivery of MOPP and ABVD combinations in Stage IV Hodgkin's disease: rationale, background studies, and recent results.
    Bonadonna G; Santoro A; Bonfante V; Valagussa P
    Cancer Treat Rep; 1982 Apr; 66(4):881-7. PubMed ID: 6176323
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Radiation as salvage therapy for patients with Hodgkin's disease relapsing after MOPP (mechlorethamine, vincristine, prednisone, and procarbazine) chemotherapy.
    Diehl LF; Perry DJ; Terebelo H; Baldwin PE; Hurwitz M; Kimball DB; Dorn RV
    Cancer Treat Rep; 1983 Sep; 67(9):827-9. PubMed ID: 6883360
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prognostic factors for Stage IV Hodgkin's disease treated with MOPP, with or without bleomycin.
    Pillai GN; Hagemeister FB; Velasquez WS; Sullivan JA; Johnston DA; Butler JJ; Shullenberger CC
    Cancer; 1985 Feb; 55(4):691-7. PubMed ID: 2578302
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Radiation therapy versus combination chemotherapy in the treatment of early-stage Hodgkin's disease: seven-year results of a prospective randomized trial.
    Longo DL; Glatstein E; Duffey PL; Young RC; Hubbard SM; Urba WJ; Wesley MN; Raubitschek A; Jaffe ES; Wiernik PH
    J Clin Oncol; 1991 Jun; 9(6):906-17. PubMed ID: 2033427
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Etoposide, vinblastine, and doxorubicin: an active regimen for the treatment of Hodgkin's disease in relapse following MOPP. Cancer and Leukemia Group B.
    Canellos GP; Petroni GR; Barcos M; Duggan DB; Peterson BA
    J Clin Oncol; 1995 Aug; 13(8):2005-11. PubMed ID: 7636541
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Adriamycin, bleomycin, DIC, CCNU, and prednisone (ABDIC) chemotherapy in MOPP-resistant Hodgkin's disease.
    Rodgers RW; Gamble JF; Loh KK; Shullenberger CC
    Cancer; 1980 Dec; 46(11):2349-55. PubMed ID: 6159961
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Free-from-failure survival in Hodgkin's disease. Long-term analysis of 148 cases treated with a MOPP-modified protocol.
    Silingardi V; Federico M; Frassoldati A; Barbieri F; Palomba G; Mauri C
    Acta Haematol; 1989; 82(4):179-86. PubMed ID: 2511719
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Treatment of advanced Hodgkin's disease: 10-year experience in the Eastern Cooperative Oncology group.
    Glick JH; Barnes JM; Bakemeier RF; Prosnitz LR; Bennett JM; Neiman RS; Costello W; Orlow EL
    Cancer Treat Rep; 1982 Apr; 66(4):855-70. PubMed ID: 7042087
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A new combination chemotherapy for recurrent Hodgkin's lymphoma.
    Rahim MA; Sarma SK; Ahmed Q
    Bangladesh Med Res Counc Bull; 1982 Dec; 8(2):63-7. PubMed ID: 6897860
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Can MOPP be replaced in the treatment of advanced Hodgkin's disease?
    Canellos GP
    Semin Oncol; 1990 Feb; 17(1 Suppl 2):2-6. PubMed ID: 1689509
    [TBL] [Abstract][Full Text] [Related]  

  • 19. British National Lymphoma Investigation randomised study of MOPP (mustine, Oncovin, procarbazine, prednisolone) against LOPP (Leukeran substituted for mustine) in advanced Hodgkin's disease--long term results.
    Hancock BW; Vaughan Hudson G; Vaughan Hudson B; Haybittle JL; Bennett MH; MacLennan KA; Jelliffe AM
    Br J Cancer; 1991 Apr; 63(4):579-82. PubMed ID: 2021542
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Randomized study for the treatment of advanced Hodgkin's disease: MOPP vs. LOPP.
    Avilés A; Díaz-Maqueo JC; García EL; Torras V; López-Vancell D
    Arch Invest Med (Mex); 1991; 22(1):45-50. PubMed ID: 1819976
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.